Antihypertensive efficacy of single-pill combinations (SPCs) consisting of a β 1 -selective adrenergic blocker with vasodilatory properties via β 3 -agonism (nebivolol) and an angiotensin II receptor blocker (valsartan) was demonstrated in an 8-week phase 3 trial (NCT01508026). In this post hoc analysis, seated blood pressure, heart rate, 24-hour ambulatory blood pressure monitoring, plasma aldosterone, estimated glomerular filtration rate, and safety measures were assessed in obese (body mass index >32 kg/m 2 ; This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modification or adaptations are made.
| INTRODUCTION
Controlling blood pressure (BP) is an important health priority to reduce the serious health consequences associated with hypertension, such as heart failure, stroke, and end-stage renal failure. 1, 2 Hypertension is uncontrolled in approximately 50% of the more than one third of Americans older than 20 years who have hypertension, 3 and nearly 400 000 deaths annually have been attributed to complications associated with this condition. A key risk factor for developing hypertension is being overweight or obese. 2, 4, 5 Hypertension has been associated with lifestyle factors that lead to obesity, including physical inactivity, high caloric intake, and poor diet. 6 Approximately 41% of obese Americans have hypertension.
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While lifestyle changes are recommended for patients with hypertension (especially those with obesity-related hypertension), many are unable to control their BP through lifestyle or diet modifications alone.
The pathogenesis of obesity-related hypertension is multifactorial and involves neural, hormonal, renovascular, and immune systems. Obesity directly 8 or indirectly 9 activates the sympathetic nervous system, 10 resulting in increased activity of the renin-angiotensin-aldosterone system (RAAS). Along with elevated BP, obese individuals-particularly those with excess abdominal fat-are more likely to have increased cardiac output and higher aldosterone plasma levels, leptin, and fasting insulin levels. 11, 12 These obesity-related effects can complicate the effective management of hypertension with antihypertensive drugs.
Based on the underlying pathophysiology of the obese population with hypertension, we reviewed the efficacy of the nebivolol and valsartan single-pill combination (SPC) in a large (N=4118), phase 3 randomized trial of adults with hypertension by obesity status. 
| METHODS

| Study design
The details of the phase 3, multicenter, randomized, double-blind, 
| Participants
| Study procedures
Seated BP was measured using an automatic monitoring device (Omron HEM-705CP, Lake Forest, IL, USA). After a 5-minute rest, four seated BP measurements were taken 2 to 5 minutes apart; the mean of the last three values constituted the BP for the visit. HR was measured via electrocardiography at screening, baseline, and week 8.
For the ABPM/biomarkers substudy, ABPM measurements were recorded at baseline and at week 8 using a Spacelabs 90207 (Snoqualmie, WA, USA) oscillometric device that was set to automatically measure and record BP; data were processed by BioClinica on the ITT population using an LOCF approach for missing data. 
| RESULTS
| Baseline characteristics
| BP measurements
| Clinic BP (pooled doses)
At week 8, all pooled active treatments significantly reduced DBP and SBP from baseline vs placebo regardless of obesity status ( Figure 1A,B) . In both BMI groups, the SPCs significantly lowered DBP and SBP vs nebivolol and valsartan monotherapies ( Figure 1C,D) .
In the obese participants, nebivolol treatment resulted in signifi- 
| Clinic BP (5/80 dose)
At week 4, significantly greater BP-lowering effects were observed with the 5/80 SPC vs nebivolol 5 mg and valsartan 80 mg monotherapies regardless of obesity status (Figure 2A 
| ABPM 24-hour substudy (pooled doses)
At week 8, all active pooled doses numerically reduced 24-hour ambulatory DBP and SBP from baseline vs placebo regardless of obesity status ( Figure 3 ). The SPCs had numerically greater DBP-and SBPlowering effects than nebivolol or valsartan alone in obese and nonobese individuals. Nebivolol had a numerically greater BP-lowering effect vs valsartan in both BMI groups (Figure 3 ).
| Heart rate
In both BMI groups, the pooled SPC and nebivolol doses significantly lowered HR vs placebo and pooled valsartan at week 8 ( Figure 4 ).
HRs were similar between pooled SPC-treated participants and those treated with pooled nebivolol monotherapy.
| Biomarkers substudy (pooled doses)
In participants who had both baseline and postbaseline values at week 4 (ITT population of the ABPM-biomarkers substudy), baseline geometric mean aldosterone concentration per treatment group ranged from 51.4 to 61.3 pg/mL for obese participants and from 51.5 to 61.6 pg/mL for nonobese individuals. At week 4, the SPCs and nebivolol monotherapies reduced plasma aldosterone from baseline in both BMI groups ( Figure   S1A ). At week 8, the SPCs numerically decreased plasma aldosterone concentrations from baseline vs placebo in both BMI groups and compared with valsartan in the obese group ( Figure S1B ). Nebivolol numerically reduced aldosterone vs placebo regardless of BMI, and numerically reduced aldosterone over valsartan in the obese participants. The nonobese placebo group had a 63.9% increase in plasma aldosterone at week 8.
| eGFR (pooled doses)
In participants who had both baseline and postbaseline values at week 8, mean baseline eGFR per treatment group ranged from 
| Potassium (nonpooled doses)
Increases in potassium levels with active treatment were generally similar to those observed in the placebo group at week 4 regardless of obesity status (see Table S1 ). At week 8, the nonobese SPC group had a numerically greater increase in potassium than placebo-treated participants (3.2% SPC vs 0% placebo).
| DISCUSSION
In this analysis from a large phase 3, placebo-controlled trial, the BP- In the biomarkers substudy, aldosterone levels generally declined with treatment regardless of obesity status. As expected, the reduc- 
STUDY LIMITATIONS
Key limitations of this analysis are its post hoc status and the small sample size of the ABPM substudy. Additionally, the nonobese placebo group had a higher percentage of Hispanics than the other nonobese pooled treatment groups. A greater placebo response has been observed in Hispanic participants in phase 3 nebivolol and nebivolol/valsartan clinical trials, 13, 29 thus the placebo response in this study may be overestimated. Despite this aberration, the nebivolol/ valsartan SPC was still more effective than placebo in this group.
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In spite of nominal reductions in aldosterone levels, especially with 
CONCLUSIONS
This post hoc analysis of the only FDA-approved SPC for hypertension comprising a β-blocker and a RAAS inhibitor suggests that nebivololvalsartan SPCs are efficacious in reducing BP in individuals regardless of obesity status. In addition, significant reductions in aldosterone levels were evident in both obese and nonobese participants compared with placebo.
